IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

NCT07483554 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

389

Enrollment

INDUSTRY

Sponsor class

Conditions

CLDN18.2 Positive
Gastric/Gastroesophageal Junction Adenocarcinoma
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: IBI343,Gemcitabine, Albumin-bound Paclitaxel

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.